Samsung Biologics Co.,Ltd. (207940.KS)
KRW 959000.0
(-2.14%)
KRW 959000.0
(-2.14%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 3694.58 Billion | 3001.29 Billion | 1568 Billion | 1164.77 Billion | 701.59 Billion | 535.8 Billion |
| Cost of Revenue | 1891.82 Billion | 1532.84 Billion | 841.55 Billion | 748.7 Billion | 509.58 Billion | 390.64 Billion |
| Gross Profit | 1802.76 Billion | 1468.44 Billion | 726.45 Billion | 416.07 Billion | 192 Billion | 145.15 Billion |
| Operating Expenses | 638.51 Billion | 484.82 Billion | 189.14 Billion | 123.28 Billion | 100.26 Billion | 89.48 Billion |
| Selling, General and Administrative Expenses | 556.93 Billion | 209.49 Billion | 103 Billion | 57.76 Billion | 56.35 Billion | 42.99 Billion |
| Research and Development Expenses | 81.58 Billion | 45.88 Billion | 75.95 Billion | 5.1 Billion | 48.5 Billion | - |
| Other Expenses | - | 229.44 Billion | 86.13 Billion | 60.42 Billion | 43.9 Billion | -6.93 Billion |
| Cost and Expenses | 2538.59 Billion | 2017.66 Billion | 1030.69 Billion | 871.99 Billion | 609.84 Billion | 480.12 Billion |
| Operating Income | 1155.98 Billion | 983.62 Billion | 537.3 Billion | 292.78 Billion | 180.61 Billion | 55.67 Billion |
| Interest Expense | 81.59 Billion | 64.06 Billion | 14.7 Billion | 16.08 Billion | 25.61 Billion | 15.83 Billion |
| Income Tax Expense | 262.29 Billion | 210.96 Billion | 167.69 Billion | 25.01 Billion | -47.46 Billion | 78.86 Billion |
| Earnings before Tax | 1119.98 Billion | 1009.02 Billion | 561.28 Billion | 265.99 Billion | 155.43 Billion | 302.97 Billion |
| Net Income | 857.69 Billion | 798.05 Billion | 393.58 Billion | 240.97 Billion | 202.9 Billion | 224.1 Billion |
| Earnings Per Share Basic | 12.05 Thousand | 11.44 Thousand | 5886.12 | 3603.77 | 3034.43 | 3351.55 |
| Earnings Per Share Diluted | 12.05 Thousand | 11.43 Thousand | 5886.12 | 3603.77 | 3034.43 | 3351.42 |
| Weighted Average Shares Outstanding | 71.17 Million | 69.74 Million | 66.86 Million | 66.86 Million | 66.86 Million | 66.86 Million |
| Weighted Average Shares Outstanding (Diluted) | 71.17 Million | 69.8 Million | 66.86 Million | 66.86 Million | 66.86 Million | 66.86 Million |
| Gross Margin | 0.49 | 0.49 | 0.46 | 0.36 | 0.27 | 0.27 |
| EBIT Margin | 0.43 | 0.46 | 0.47 | 0.37 | 0.45 | 0.77 |
| Profit Margin | 0.23 | 0.27 | 0.25 | 0.21 | 0.29 | 0.42 |
| EBITDA | 1603.46 Billion | 1354.09 Billion | 723.92 Billion | 443.02 Billion | 240.65 Billion | 410.26 Billion |
| Earnings Before Tax Margin | 0.31 | 0.33 | 0.34 | 0.25 | 0.26 | 0.10 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 1187.07 Billion | 1156.9 Billion | 946.9 Billion | 3694.58 Billion | 1073.5 Billion | 1033.97 Billion |
| Cost of Revenue | - | 509.15 Billion | 536.43 Billion | 1891.82 Billion | 542.24 Billion | 532.15 Billion |
| Gross Profit | 1187.07 Billion | 647.74 Billion | 410.46 Billion | 1802.76 Billion | 531.26 Billion | 501.81 Billion |
| Operating Expenses | 848.49 Billion | 722.39 Billion | 725.6 Billion | 2580.9 Billion | 723.54 Billion | -183.28 Billion |
| Selling, General and Administrative Expenses | - | 180.53 Billion | 162.88 Billion | - | 73.41 Billion | 183.28 Billion |
| Research and Development Expenses | - | 26.58 Billion | 24.57 Billion | - | 22.4 Billion | 21.11 Billion |
| Other Expenses | -848.49 Billion | -722.39 Billion | -725.6 Billion | -2580.9 Billion | -723.54 Billion | -366.56 Billion |
| Cost and Expenses | 848.49 Billion | 722.39 Billion | 725.6 Billion | 2580.9 Billion | 723.54 Billion | 532.15 Billion |
| Operating Income | 338.57 Billion | 434.51 Billion | 221.29 Billion | 1113.68 Billion | 349.96 Billion | 318.53 Billion |
| Interest Expense | - | - | - | 81.59 Billion | 19.47 Billion | 21.63 Billion |
| Income Tax Expense | 26.53 Billion | 146.96 Billion | 60.71 Billion | 262.29 Billion | 65.02 Billion | 75.94 Billion |
| Earnings before Tax | 290.99 Billion | 464.96 Billion | 240.07 Billion | 1119.98 Billion | 355.71 Billion | 316.31 Billion |
| Net Income | 264.46 Billion | 317.99 Billion | 179.36 Billion | 857.69 Billion | 290.68 Billion | 240.36 Billion |
| Earnings Per Share Basic | 3715.80 | 4467.81 | 2520.05 | - | 4084.13 | 3377.17 |
| Earnings Per Share Diluted | 3715.80 | 4467.81 | 2520.05 | - | 4084.13 | 3377.17 |
| Weighted Average Shares Outstanding | 71.17 Million | 71.17 Million | 71.17 Million | 71.17 Million | 71.17 Million | 71.17 Million |
| Weighted Average Shares Outstanding (Diluted) | 71.17 Million | 71.17 Million | 71.17 Million | 71.17 Million | 71.17 Million | 71.17 Million |
| Gross Margin | 1.00 | 0.56 | 0.43 | 0.49 | 0.49 | 0.49 |
| EBIT Margin | 0.29 | 0.38 | 0.23 | - | 0.48 | 0.49 |
| Profit Margin | 0.22 | 0.27 | 0.19 | 0.23 | 0.27 | 0.23 |
| EBITDA | 338.57 Billion | 434.51 Billion | 221.29 Billion | - | 514.72 Billion | 501.81 Billion |
| Earnings Before Tax Margin | 0.29 | 0.38 | 0.23 | 0.30 | 0.33 | 0.31 |
5542
M2R
9526
BCHN
7883
1108